scholarly journals Antithrombotic Treatment After Coronary Intervention: Agreement and Controversy

2020 ◽  
Vol 15 ◽  
Author(s):  
Tamara García Camarero ◽  
José M de la Torre Hernández
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Treatment Strategies ◽  
Coronary Intervention ◽  
New Drugs ◽  
Antithrombotic Treatment ◽  
The Past ◽  
Percutaneous Coronary ◽  
The Subject ◽  
Clinical Conditions ◽  
Combination Regimens

Percutaneous revascularisation has evolved dramatically in the past few decades. The approach to the management of ischaemic heart disease has changed due to the development of new devices and techniques as well as the availability of new drugs and treatment strategies. Its use in combination with antiplatelet therapies has been essential to protect against stent thrombosis. The length of time this combination therapy is used has been modified in recent years and has been the subject of extensive research. The effect of prolonging the time it is taken or shortening it has been evaluated in different clinical conditions. In practice, the decisions regarding antithrombotic therapy after percutaneous coronary intervention are informed by the patient’s profile and the characteristics of the procedures performed. In this article, we review the use of antiplatelet/anticoagulant therapy after percutaneous coronary intervention focusing on trials and guidelines addressing variable durations for combination regimens and the alternatives.

scholarly journals The EXCEL Trial: The Interventionalists’ Perspective

2021 ◽  
Vol 16 ◽  
Author(s):  
George William Hunter ◽  
Vinoda Sharma ◽  
Chetan Varma ◽  
Derek Connolly
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Current Literature ◽  
Coronary Intervention ◽  
Main Stem ◽  
Significant Morbidity ◽  
Left Main ◽  
New Developments ◽  
The Past ◽  
Percutaneous Coronary ◽  
Diagnostic Angiography

Left main stem (LMS) disease is identified in up to 5% of diagnostic angiography cases, and is associated with significant morbidity and mortality due to the proportion of myocardium it subtends. In the past 10 years, there has been a significant change in the way we contemplate treating lesions in the LMS due to evolving experience and evidence in percutaneous coronary intervention (PCI) strategies and technologies. This has been reflected in recent changes in European and International guidance on managing patients with this lesion subset. Here, the authors provide an overview of the current literature regarding the management of LMS disease using PCI in light of new developments and emerging concepts in this field, specifically looking at the recent EXCEL trial.

Sign in / Sign up

Export Citation Format

Share Document